Advanced search
Publication Cover
Biomarkers Volume 15, 2010 - Issue 3
Submit an article Journal homepage
100
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy

Xin An;State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, P.R. China
,
Pei-Rong Ding;Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China
,
Xiao-Juan Xiang;Department of Colorectal Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China
,
Zhi-Qiang Wang;State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, P.R. China
,
Feng-Hua Wang;Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China
,
Fen Feng;Department of Colorectal Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China
,
Wen-Qi Jiang;State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, P.R. China
,
You-Jian He;Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China
,
Rui-Hua Xu;Department of Colorectal Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China
&
Yu-Hong Li;State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, P.R. ChinaCorrespondence[email protected]
 show all
Pages 243-248 | Received 23 Sep 2009, Accepted 10 Nov 2009, Published online: 02 Feb 2010
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Abstract

Background and objective: Oxaliplatin (OXA)-induced carcinoembryonic antigen (CEA) surge was reported to be associated with a clinical benefit. The aim of this study was to investigate the phenomenon of CEA surge in irinotecan-based chemotherapy.

Methods: We retrospectively reviewed 132 patients with metastatic colorectal cancer treated with irinotecan-based chemotherapy. Incidence of a CEA surge and chemotherapy efficacy were investigated.

Results: Eleven of 99 eligible patients (11.1%) had CEA surges. None of the 11 patients showed progressive disease (four had a partial response, seven had stable disease).

Conclusion: A CEA surge can be induced by irinotecan-based chemotherapy. An early increase in CEA after irinotecan-based chemotherapy does not usually indicate progression of disease and failure of therapy, and should not lead to a change of chemotherapy.

Acknowledgement

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 527.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.